GB1115849A - Process for the preparation of a stable, hepatitis-virus free serum - Google Patents

Process for the preparation of a stable, hepatitis-virus free serum

Info

Publication number
GB1115849A
GB1115849A GB10621/66D GB1062166D GB1115849A GB 1115849 A GB1115849 A GB 1115849A GB 10621/66 D GB10621/66 D GB 10621/66D GB 1062166 D GB1062166 D GB 1062166D GB 1115849 A GB1115849 A GB 1115849A
Authority
GB
United Kingdom
Prior art keywords
serum
silicic acid
free
sterile
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB10621/66D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Serum Institut GmbH
Original Assignee
Biotest Serum Institut GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1966B0089704 external-priority patent/DE1617335B2/en
Application filed by Biotest Serum Institut GmbH filed Critical Biotest Serum Institut GmbH
Publication of GB1115849A publication Critical patent/GB1115849A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods

Abstract

Lipo-protein-free, hepatitis-virus-free, fibrinogen-free stable and sterile serum is prepared by intimately mixing blood serum or blood plasma with 250 to 545 mg of colloidal silicic acid per gram of total protein in the serum and, after separating the silicic acid containing lipoproteins and fibrinogen, irradiating the serum with U.V. light and then filtering sterile or vice versa. The process may be carried out at up to 50 DEG C. with a pH range of 6.5 to 8 and U.V. irradiation intensity of 1 milliwatt/cm2 minute. The sterile filtration is preferably interposed between the adsorbtion operation and the U.V. irradiation and may involve using asbestos-containing filters impervious to bacteria with a pore diameter of 0.9 to 1.2m or a milli pore sieve membrane with a pore diameter of 0.22m \sB 10%. The silicic acid precipitate may be treated with concentrated salt solutions in the alkaline pH range (preferably saturated Na Cl solution at pH 9.0) to obtain a lipoprotein solution.
GB10621/66D 1966-04-06 1967-03-07 Process for the preparation of a stable, hepatitis-virus free serum Expired GB1115849A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEB0086560 1966-04-06
DE1966B0089704 DE1617335B2 (en) 1966-11-05 1966-11-05 PROCESS FOR MANUFACTURING LIPOPROTEIN-FREE, STABLE AND STERILE SERUM
DEB0091011 1967-02-02

Publications (1)

Publication Number Publication Date
GB1115849A true GB1115849A (en) 1968-05-29

Family

ID=27209344

Family Applications (1)

Application Number Title Priority Date Filing Date
GB10621/66D Expired GB1115849A (en) 1966-04-06 1967-03-07 Process for the preparation of a stable, hepatitis-virus free serum

Country Status (8)

Country Link
US (1) US3686395A (en)
AT (1) AT270868B (en)
BE (1) BE696020A (en)
FR (1) FR7395M (en)
GB (1) GB1115849A (en)
NL (1) NL6702923A (en)
SE (1) SE328089B (en)
SU (1) SU477580A3 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822095A (en) * 1972-08-14 1974-07-02 Block Engineering System for differentiating particles
DE2364317C3 (en) * 1973-12-22 1979-10-11 Behringwerke Ag, 3550 Marburg Procedure for the isolation of choleragen
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
DK139056B (en) * 1976-04-06 1978-12-11 Nordisk Insulinlab Method for recovering immunoglobulin suitable for intravenous administration.
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
JPS5446813A (en) * 1977-09-22 1979-04-13 Toyo Soda Mfg Co Ltd Separation of plasmaprotein
DE2837168A1 (en) * 1978-08-25 1980-03-06 Blutspendedienst Dt Rote Kreuz METHOD FOR PRODUCING AN IMMUNAL GLOBULIN SOLUTION SUITABLE FOR INTRAVENOUS APPLICATION
US4228154A (en) * 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4251510A (en) * 1979-08-15 1981-02-17 Cutter Laboratories, Inc. Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
US4511473A (en) * 1982-02-09 1985-04-16 Amf Incorporated Fibrous media containing millimicron-sized particulates
US4578150A (en) * 1982-07-23 1986-03-25 Amf Inc. Fibrous media containing millimicron-sized particulates
DE3247150A1 (en) * 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt CLOTHING ACTIVE PLASMA PROTEIN REDUCTION, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR TREATING DISORDERS OF THE HAEMOSTASE SYSTEM
US4533634A (en) * 1983-01-26 1985-08-06 Amf Inc. Tissue culture medium
AU2492084A (en) * 1983-01-26 1984-08-15 Amf Inc. Tissue culture medium
US4639513A (en) * 1984-02-02 1987-01-27 Cuno Inc. Intravenously injectable immunoglobulin G (IGG) and method for producing same
DE3483751D1 (en) * 1983-05-02 1991-01-31 Diamond Scient Co PHOTOCHEMICAL DISABLING TREATMENT OF FULL BLOOD OR BLOOD COMPONENTS.
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
DE3330770A1 (en) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg METHOD FOR PASTEURIZING HUMAN PLASMA
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
NL9401535A (en) * 1994-09-21 1996-05-01 Stichting Scheikundig Onderzoe Serum-prepared protein mixture for use as a component in media for in vitro culture of animal cells.
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469193A (en) * 1942-02-09 1949-05-03 Research Corp Protein fractionation
US3284434A (en) * 1960-08-29 1966-11-08 Univ Kansas State Protein isolation and preparations

Also Published As

Publication number Publication date
NL6702923A (en) 1967-10-09
SE328089B (en) 1970-09-07
BE696020A (en) 1967-09-25
AT270868B (en) 1969-05-12
SU477580A3 (en) 1975-07-15
FR7395M (en) 1969-11-03
US3686395A (en) 1972-08-22

Similar Documents

Publication Publication Date Title
GB1115849A (en) Process for the preparation of a stable, hepatitis-virus free serum
DE3930510A1 (en) PROCESS FOR INACTIVATING VIRUSES IN BLOOD AND BLOOD PRODUCTS
DE3174380D1 (en) Hemofiltration system
DD298110A5 (en) METHOD FOR PRODUCING A CONCENTRATE OF THE BLOOD GENERATION FACTOR VIII FROM WILLEBRAND FACTOR COMPLEX FROM ENTIRE PLASMA
KR890006251A (en) Process for the preparation of high-purity, virus-activated biologically active transferrin preparations
DE3369998D1 (en) Plasma protein solution with a clotting activity, process for its preparation and its use in the treatment of disorders of the hemostatic system
CN111012726A (en) A method for preparing Lumbricus extract with skin aging resisting effect
GB1504334A (en) Production of solutions
DE1617319C3 (en)
JPS6475092A (en) Preparation of ultra-pure water
ATE88752T1 (en) INACTIVATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PROTEIN SOLUTIONS BY PHENOLS.
PL85201B1 (en)
RU94016976A (en) METHOD OF OBTAINING INDIA GENERATOR - 113M
JPH0114788B2 (en)
RU2053777C1 (en) Composition for osteogenesis activation
SU86156A1 (en) The method of cleaning diffusion juice
SU765355A1 (en) Method of wine stabilizing
RU2042358C1 (en) Method of preparing factor ix concentrate
SU461612A1 (en) Water purification method
GB282165A (en) Improvements in the purification and softening of water
SU1367228A1 (en) METHOD OF OBTAINING CAPSULATED HEMOSORBENT
SU1748411A1 (en) Method of extraction of pentavalent arsenic from the aqueous solution
JP3036900U (en) Bath water purification device using titanium dioxide
JPS6438097A (en) Method for reactivating protein
CN110564796A (en) Production process of hydrolyzed collagen